Adjuvant Treatment Modalities, Prognostic Factors, and Outcome of the Uterine Carcinosarcoma.


Journal

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC
ISSN: 1701-2163
Titre abrégé: J Obstet Gynaecol Can
Pays: Netherlands
ID NLM: 101126664

Informations de publication

Date de publication:
01 2021
Historique:
received: 13 04 2020
revised: 20 06 2020
accepted: 24 06 2020
pubmed: 13 10 2020
medline: 1 7 2021
entrez: 12 10 2020
Statut: ppublish

Résumé

To determine the impact of adjuvant therapy and other factors associated with the recurrence and survival of patients with uterine carcinosarcoma (UCS). A total of 102 patients who underwhent surgery for UCS from 1998 to 2017 were included in the analysis. Data were analyzed using Kaplan-Meier methods and Cox proportional hazards regression. At 240 months, the actuarial recurrence rate was 34.3%. Distant recurrence was the most common recurrence pattern. Patients with higher CA 125 levels, sarcoma dominance, cervical involvement, advanced stage, no lymphadenectomy, and residual tumour had a significiantly higher risk of recurrence. Five-year disease-free survival (DFS) and overall survival (OS) were 67% and 77%, respectively. FIGO stage was found to be an independent prognostic factor for DFS and OS. Sarcoma dominance was independently associated with decreased OS. Sarcoma dominance is associated with poor survival in UCS. Adjuvant treatment was not found to affect recurrence or survival. Given this finding, more effective postoperative strategies are needed.

Identifiants

pubmed: 33041218
pii: S1701-2163(20)30542-9
doi: 10.1016/j.jogc.2020.06.021
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

34-42

Informations de copyright

Copyright © 2020 The Society of Obstetricians and Gynaecologists of Canada/La Société des obstétriciens et gynécologues du Canada. Published by Elsevier Inc. All rights reserved.

Auteurs

Ilker Kahramanoglu (I)

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. Electronic address: ilkerkahramanoglu@gmail.com.

Fuat Demirkiran (F)

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.

Hasan Turan (H)

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.

Tugan Bese (T)

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.

Sukru Cebi (S)

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.

Sennur Ilvan (S)

Department of Pathology, Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.

Macit Arvas (M)

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH